3zd0: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==The Solution Structure of Monomeric Hepatitis C Virus p7 Yields Potent Inhibitors of Virion Release== | |||
<StructureSection load='3zd0' size='340' side='right' caption='[[3zd0]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[3zd0]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/9hepc 9hepc]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3ZD0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3ZD0 FirstGlance]. <br> | |||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3zd0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3zd0 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3zd0 RCSB], [http://www.ebi.ac.uk/pdbsum/3zd0 PDBsum]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Current interferon-based therapy for hepatitis C virus (HCV) infection is inadequate, prompting a shift towards combinations of direct-acting antivirals (DAA) with the first protease-targeted drugs licensed in 2012. Many compounds are in the pipeline yet primarily target only three viral proteins, namely NS3/4A protease, NS5B polymerase and NS5A. With concerns growing over resistance, broadening the repertoire for DAA targets is a major priority. Here we describe the complete structure of the HCV p7 protein as a monomeric hairpin, solved using a novel combination of chemical shift and NOE based methods. This represents atomic resolution information for a full-length virus-coded ion channel, or "viroporin", whose essential functions represent a clinically proven class of antiviral target exploited previously for influenza A virus therapy. Specific drug-protein interactions validate an allosteric site on the channel periphery and its relevance is demonstrated by the selection of novel, structurally diverse inhibitory small molecules with nanomolar potency in culture. Hit compounds represent a 10,000-fold improvement over prototypes, suppress rimantadine resistance polymorphisms at sub-micromolar concentrations and show activity against other HCV genotypes. Conclusions: This proof-of-principle that structure-guided design can lead to drug-like molecules affirms p7 as a much needed new target in the burgeoning era of HCV DAA. (Hepatology 2013;). | |||
Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release.,Foster TL, Thompson GS, Kalverda AP, Kankanala J, Bentham M, Wetherill LF, Thompson J, Barker AM, Clarke D, Noerenberg M, Pearson AR, Rowlands DJ, Homans SW, Harris M, Foster R, Griffin S Hepatology. 2013 Aug 12. doi: 10.1002/hep.26685. PMID:24022996<ref>PMID:24022996</ref> | |||
== | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | |||
== References == | |||
[[Category: Barker, A M | <references/> | ||
[[Category: Clarke, D | __TOC__ | ||
[[Category: Foster, R | </StructureSection> | ||
[[Category: Foster, T L | [[Category: Barker, A M]] | ||
[[Category: Griffin, S D.C | [[Category: Clarke, D]] | ||
[[Category: Harris, M | [[Category: Foster, R]] | ||
[[Category: Homans, S W | [[Category: Foster, T L]] | ||
[[Category: Kalverda, A P | [[Category: Griffin, S D.C]] | ||
[[Category: Kankanala, J | [[Category: Harris, M]] | ||
[[Category: Noerenberg, M | [[Category: Homans, S W]] | ||
[[Category: Pearson, A R | [[Category: Kalverda, A P]] | ||
[[Category: Rowlands, D J | [[Category: Kankanala, J]] | ||
[[Category: Sthompson, G | [[Category: Noerenberg, M]] | ||
[[Category: Thompson, J | [[Category: Pearson, A R]] | ||
[[Category: Rowlands, D J]] | |||
[[Category: Sthompson, G]] | |||
[[Category: Thompson, J]] | |||
[[Category: Antiviral]] | [[Category: Antiviral]] | ||
[[Category: Ion channel]] | [[Category: Ion channel]] | ||
[[Category: Transport protein]] | [[Category: Transport protein]] | ||
[[Category: Viroporin]] | [[Category: Viroporin]] | ||
Revision as of 09:40, 22 January 2015
The Solution Structure of Monomeric Hepatitis C Virus p7 Yields Potent Inhibitors of Virion ReleaseThe Solution Structure of Monomeric Hepatitis C Virus p7 Yields Potent Inhibitors of Virion Release
Structural highlights
Publication Abstract from PubMedCurrent interferon-based therapy for hepatitis C virus (HCV) infection is inadequate, prompting a shift towards combinations of direct-acting antivirals (DAA) with the first protease-targeted drugs licensed in 2012. Many compounds are in the pipeline yet primarily target only three viral proteins, namely NS3/4A protease, NS5B polymerase and NS5A. With concerns growing over resistance, broadening the repertoire for DAA targets is a major priority. Here we describe the complete structure of the HCV p7 protein as a monomeric hairpin, solved using a novel combination of chemical shift and NOE based methods. This represents atomic resolution information for a full-length virus-coded ion channel, or "viroporin", whose essential functions represent a clinically proven class of antiviral target exploited previously for influenza A virus therapy. Specific drug-protein interactions validate an allosteric site on the channel periphery and its relevance is demonstrated by the selection of novel, structurally diverse inhibitory small molecules with nanomolar potency in culture. Hit compounds represent a 10,000-fold improvement over prototypes, suppress rimantadine resistance polymorphisms at sub-micromolar concentrations and show activity against other HCV genotypes. Conclusions: This proof-of-principle that structure-guided design can lead to drug-like molecules affirms p7 as a much needed new target in the burgeoning era of HCV DAA. (Hepatology 2013;). Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release.,Foster TL, Thompson GS, Kalverda AP, Kankanala J, Bentham M, Wetherill LF, Thompson J, Barker AM, Clarke D, Noerenberg M, Pearson AR, Rowlands DJ, Homans SW, Harris M, Foster R, Griffin S Hepatology. 2013 Aug 12. doi: 10.1002/hep.26685. PMID:24022996[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||